Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19868615 | 0.93 | SMN1; SMN2 (0.42) | GRM5SMN1; SMN2ATMNUDT1HRH4 | |
| Cyromazine SCHEMBL10832935 | 0.89 | NUDT1 (0.43) | SMN1; SMN2NUDT1HRH4PDE4APDE4B | |
| Cyromazine SCHEMBL27231 | 0.89 | NUDT1 (0.43) | SMN1; SMN2NUDT1HRH4PDE4APDE4B | |
| SCHEMBL27628560 | 0.89 | PDE4A (0.50) | GRM5SMN1; SMN2ATMNUDT1HRH4 | |
| Cyromazine SCHEMBL11476792 | 0.87 | NUDT1 (0.42) | SMN1; SMN2NUDT1HRH4PDE4APDE4B | |
| Cyromazine SCHEMBL11478220 | 0.85 | NUDT1 (0.41) | SMN1; SMN2NUDT1HRH4PDE4A | |
| SCHEMBL10706738 | 0.85 | NUDT1 (0.43) | SMN1; SMN2NUDT1HRH4PDE4A | |
| SCHEMBL11478013 | 0.81 | NUDT1 (0.49) | SMN1; SMN2NUDT1HRH4PDE4A | |
| Cyromazine SCHEMBL21494152 | 0.80 | BRAF (0.39) | NUDT1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11482610 | 0.80 | PDE4A (0.56) | SMN1; SMN2NUDT1HRH4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-11-16 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GRM5 512/4885SMN1; SMN2 4172/4885ATM 3032/4885 |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | GRM5 418/4885SMN1; SMN2 4238/4885ATM 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.